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The cAMP response element-binding protein (CREB) is a nuclear transcription factor downstream of cell surface receptors and
mitogensthatiscriticalfornormalandneoplastichematopoiesis.Previousworkfromourlaboratorydemonstratedthatamajority
of patients with acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) overexpress CREB in the bone marrow. To
understand the role of CREB in leukemogenesis, we examined the biological eﬀect of CREB overexpression on primary leukemia
cells, leukemia cell lines, and CREB overexpressing transgenic mice. Our results demonstrated that CREB overexpression leads to
an increase in cellular proliferation and survival. Furthermore, CREB transgenic mice develop a myeloproliferative disorder with
aberrant myelopoiesis in both the bone marrow and spleen. Additional research from other groups has shown that the expression
of the cAMP early inducible repressor (ICER), a CREB repressor, is also deregulated in leukemias. And, miR-34b, a microRNA that
negative regulates CREB expression, is expressed at lower levels in myeloid leukemia cell lines compared to that of healthy bone
marrow. Taken together, these data suggest that CREB plays a role in cellular transformation. The data also suggest that CREB-
speciﬁc signaling pathways could possibly serve as potential targets for therapeutic intervention.
Copyright © 2009 Salemiz Sandoval et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
CREB is a 43-kDa protein, member of the CREB/ATF-1
family of transcription factors, conserved from Drosophila
to humans [1]. In mammals, CREB family members include
CREB, cAMP-responsive element modulator (CREM), and
activating transcription factor 1 (ATF-1). CREB and ATF-
1 are ubiquitously expressed in all tissues. The expression
of CREM, however, is tissue speciﬁc and developmentally
regulated. This family of transcription factors contains
a 60 amino acid kinase-inducible domain (KID) with
several phosphorylation sites, two hydrophobic glutamine-
rich transactivation domains, Q1 and Q2, that function as
constitutive activators in vitro, and a basic leucine zipper
(bZip) dimerization domain. CREB is activated through
phosphorylation at serine 133 in response to a variety of
cellular and mitogen stress signals. These include peptide
hormones, neurotransmitters, calcium inﬂux, and growth
factors [1–3]. Upon activation, CREB binds as a dimer to the
cAMP response element (CRE), TGACGTCA, or CRE half
sites CGTCA/TGACG, where it promotes the recruitment of
thetranscriptionalcoactivatorsCREBbindingprotein(CBP)
and p300. These coactivators then promote the recruitment
of components of the basal transcriptional machinery to
initiate transcription of CREB target genes [3–5].
CREB activity is also regulated by a family of cytoplasmic
coactivatorsknownastransducersofregulatedCREBactivity
(TORCs). There are three TORC members, TORC1, TORC2,
and TORC3, and all are thought to be strong activators of
CREB-dependent transcription. These coactivators bind the
bZip domain of CREB in response to extracellular stimuli,
such as cAMP, calcium, and hormones. When activated,
TORCs are translocated into the nucleus where they activate
CREB through a phosphoserine-133 independent mecha-
nism [6, 7].
CREB has been implicated in a number of cellularevents.
CREB coactivators help discriminate between signals to
activate only speciﬁc cellular processes. However, it has been
demonstrated that the interaction between CREB and its





























Figure 1: Pathways for CREB activation in hematopoietic cells. A variety of extracellular stimuli promote CREB activation through
phosphorylation or through interaction with CREB coactivators to enhance the expression of CREB responsive genes. CREB target genes
have been shown to mediate eﬀects on cellular proliferation, apoptosis, survival, and diﬀerentiation. PLC : phospholipase-C, DAG : 1,2-
diacylglycerol, PKC-ε : protein kinase C-ε.
target genes [1]. This suggests that many CREB interacting
proteins are yet to be identiﬁed. Thus, future research should
focus on identifying CREB interacting partners that further
potentiate CREB activation or confer signal speciﬁcity.
2.CREBKinases
There are several serine/threonine kinases that have been
reported to activate CREB. Stimuli such as cAMP, calcium,
and growth factors and cellular stress activate kinases such
as ribosomal protein S6 kinase (pp90rsk), protein kinase
A (PKA), protein kinase C (PKC), protein kinase B/AKT,
and (mitogen- and stress-activated protein kinase) MSK-1,
subsequently activate CREB [2]. Mitogenic and ultraviolet
stress, for example, lead to the activation of mitogen/stresses
activated kinase-1 (MSK-1), a pp90rsk family member that
in turn phosphorylates CREB [8]. CREB phosphorylation
is abrogated in ﬁbroblasts from MSK-1/MSK-2 double
knockout mice when stimulated with mitogens or when it
is under cellular stress [9]. CREB is also phosphorylated
in response to Granulocyte-Macrophage Colony Simulating
Factor (GM-CSF) by pp90rsk in myeloid cells (Figure 1),
leading to the activation of immediate early genes, c-fos,
activator protein 1 (AP-1/junB), and early growth response
protein 1 (egr-1) [10]. And CREB activation by MAPK
and AKT/B enhances the survival of cultured cells [11].
In 2002, Raes and others characterized a new signaling
pathway leading to CREB activation. Using L929 murine
ﬁbrosarcoma and ρ0 143B human osteosarcoma cell lines,
this group demonstrated that CREB was phosphorylated
by Calmodulin kinase IV (CAMKIV) as a consequence
of mitochondrial dysfunction. In these mitochondrially
impaired cells, CREB is constitutively activated as a result of
high intracellular calcium levels that disrupt the association
between CaMKIV and the protein phosphatase 2A (PP2A),
resulting in constitutively activated CAMKIV [12]. These
CREB kinases are among a long list of kinases that activate
CREB in response of many extracellular stimuli.
3.CREB Activates Cellular Targets with Diverse
Sets of Functions
CREB has been implicated in a great number of cellular
functions, including metabolism, proliferation, apoptosis,
and diﬀerentiation. Studies have demonstrated that CREB
is phosphorylated in response to up to 300 diﬀerent stimuli
[3]. And upon activation, CREB enhances the expression
of up to 5000 putative genes [5]. More stringent genome
wideanalysisforCREBbindingmotifsidentiﬁed1349mouse
and 1663 human CREB binding sites [13]. A quarter of the
CRE-containing sequences function in cellular metabolism.
In the liver, for example, CREB regulates gluconeogenesis,
through phosphoenol pyruvate carboxykinase [14, 15].
Other metabolic enzymes, such as pyruvate carboxylase,
ornithine decarboxylase, and lactate dehydrogenase contain
CRE consensus sites in their promoters [2]. It has also
been well characterized that CREB plays a critical role in
survival. In sympathetic and cerebral neurons, nerve growthAdvances in Hematology 3
factor(NGF)andbrain-derivedneurotrophicfactor(BDNF)
stimulate survival by activating the expression of the anti-
apoptotic protein B-cell lymphoma 2 (bcl-2) [16, 17]. This
was further shown by overexpression of a dominant negative
form of CREB in these cells resulting in increased cell death.
Moreover, this eﬀect was reverted by overexpression of bcl-2.
CREB has also been shown to regulate proliferation through
cyclins A1 and D1 [2, 18, 19]. For instance, knockdown of
CREB in both TF-1 and K562 cells leads to a decrease in the
expression of cell cycle regulators, Cyclin A1 (Figure 1)a n d
Cyclin D1.
Furthermore, CRE-binding proteins have been shown
to play a role in the physiology of the pituitary gland, in
regulating spermatogenesis and circadian rhythm, and in
learning and memory [20]. The functional diversity of the
proteins CREB regulates suggests that cell surface proteins
or CREB signaling molecules must confer speciﬁcity or
allow for discrimination between signal inputs to activate
particular cellular processes.
4. Role of CREB in Cancer
Many of the CREB target genes identiﬁed function in
cell growth, survival, and cell-cycle regulation, and their
aberrant expression has been associated with cancer. The
genes identiﬁed include genes that enhance proliferation,
cell cycle progression, and survival, such as c-fos, cyclins
A1 and D1, and survival, such as the bcl-2 protein. A role
for CREB family members in cancer was ﬁrst identiﬁed in
clear-cell sarcomas of the soft tissues (CSSTs). Most CSSTs
contain the chromosomal translocation t(12;22)(q13;q12)
that fuses the DNA-binding and bZip domain of ATF1 to the
Ewing’s sarcoma gene, EWS. The EWS-ATF1 fusion protein
promotes proliferation and inhibits apoptosis [21–23].
Recently, an EWS-CREB fusion protein was also identiﬁed in
a subset of CSST patients [24]. EWS-ATF1 and EWS-CREB
fusion onco-proteins are constitutively active and enhance
the expression of CREB target genes, independent of growth
or signal stimulus.
Interestingly, CREB is also required for viral trans-
formation of T lymphocytes by the oncogenic retrovirus
human T-cell leukemia virus (HTLV-I). HTLV-I causes adult
T cell leukemia, an aggressive neoplasm that results in
the increase in the responsiveness of cells to extracellular
stimuli enhancing their proliferation and survival while
inhibiting apoptosis. Tax, an oncogenic viral protein of
HTLV-I, physically interacts with CREB to potentiate CREB
dimerization and DNA binding to allow for the recruitment
of the coactivators p300 and CBP in the absence of serine-
133 phosphorylation [25]. Tax has also been shown to
bind TORCs to potentiate CREB activation and increase the
transcription of viral and cellular targets of CREB [26, 27].
Another oncogenic retrovirus, Hepatitis B virus (HBV), has
also been shown to promote cellular transformation by
enhancing CREB target gene expression in a similar way to
HTLV-1. HBV interacts with CREB/ATF2 and p300/CBP to
constitutively turn on CREB genes [28].
TORCs, CREB coactivators, have also been implicated in
cancers. TORCs are deregulated in mucoepidermoid carci-
nomas, a salivary gland tumor that possesses a t(11;19)(q14–
21;p12–13) translocation. This translocation fuses the N-
terminal amino acids of TORC1 to the epidermoid car-
cinoma translocated-1 (METC-1) to the transcriptional
activation domain of the Notch co-activator Mastermind-
like2(MAML2).TheTORC1-MAML2fusionproteinretains
the CREB binding domain, which activates the transcription
of CREB cellular targets [6, 29]. It has been well documented
that TORC1-MAML2 but not TORC1 or MAML2 can
transform cells [30]. Moreover, a dominant form of CREB,
lacking the ability to bind DNA, cannot transform cells [31].
CREB has also been implicated in many other can-
cers, some of which include hepatocellular carcinoma,
osteosarcoma, lung adenocarcinoma, and leukemias [32].
This evidence suggests that CREB as a fusion protein or
by cooperation with other oncogenes can promote cellular
transformation [33].
5. CREB is Key Regulator of Hematopoiesis and
Leukemogenesis
Hematopoiesis involves the expansion and diﬀerentiation
of a small population of pluripotent stem cells into pro-
genitor cells. Maturation of these stem cells requires the
exposure of these cells to a combination of diﬀerentiation
and growth signals. CREB is downstream of cell surface
receptors and mitogens that control normal hematopoiesis
and leukemogenesis. Recent studies have demonstrated that
CREB modulates the expression of genes that regulate
hematopoiesis [20, 34]. In the human erythroid cell line, TF-
1 for example, CREB was shown to regulate the expression
of immediate early gene, egr-1 [10, 35]. In these cells,
interleukin-3 (IL-3) and GM-CSF signaling results in CREB
activation of egr-1 in response to pp90RSK activation
through a Mitogen-activated protein/extracellular regulated
kinase- (MEK-) dependant signaling pathway. Other studies
have shown that IL-3 and GM-CSF, but not IL-4, potentiate
CREB activation through PKC-ε in TF-1 cells [36]. Egr-
1 is critical for transcription of myeloid-speciﬁc proteins
that function as determinants of myeloid cell proliferation
and diﬀerentiation. CREB also appears to play a role in
megakaryocytic diﬀerentiation [36]. Studies performed in
the biphenotypic cell line, HEL (erythroid/megakaryocytic),
and CD34+ cells from normal patients show that throm-
bopoietin (TPO), and forskolin (FK), and phorbol myristate
acetate(PMA)leadstoincreasedactivationofCREBthrough
a Mitogen-activated protein kinase- (MAPK-) dependent
mechanism [37].
Our group has provided additional evidence for the
role of CREB in hematopoiesis. Expression analysis of both
murine and human primary cells revealed that CREB is
highly expressed in stem cells and uncommitted progen-
itors [19]. A 2.6-fold increase in CREB expression was
observed in committed marker lineage-negative stem cells
and progenitors compared to diﬀerentiated lineage-positive
murine bone marrow cells. Further fractionation of bone
marrow cells showed that CREB expression was increased
in hematopoietic stem cells (HSCs), common myeloid
progenitors (CMPs), granulocyte-macrophage progenitors4 Advances in Hematology
(GMPs), and megakaryocytic erythroid progenitors (MEPs).
Analysis of human stem cells conﬁrmed these results,
showing that CREB expression was increased by twofold
in immature committed marker lineage-negative, CD34
positive hematopoietic cells compared to diﬀerentiated com-
mittedmarkerlineage-positiveCD34negativehematopoietic
cells from both cord and peripheral blood [19].
To further investigate the requirement of CREB in
normal hematopoiesis, normal murine bone marrow and
human peripheral blood stem cells (PBSCs) were transduced
with CREB lentiviral shRNAs. Colony assays demonstrated
that CREB inhibition aﬀected growth and increased apop-
tosis in knockdown cells compared to vector controls
[19]. CREB downregulation also signiﬁcantly decreased the
number of CFU-GM colonies in both murine bone marrow
cells and human PBSCs. Collectively, these data demonstrate
thatCREBdownregulationresultsinabnormalproliferation,
survival, and cell-cycle regulation of normal hematopoietic
cells.
In addition to playing a role in normal hematopoiesis,
CREB has also been shown to potentiate transformation of
hematopoietic cells. As mentioned earlier, CREB has been
linked to the pathogenesis of HTLV-1 leukemias by Tax, a
viral transcription factor that enhances CREB activation
[32, 33]. CREB has also been implicated in the pathogenesis
of lymphomas. CREB activates the transcription of bcl-2,
an antiapoptotic protein in follicular lymphomas bearing
the t(14;18) translocation [38, 39]. Studies show that CREB
binds and enhances the expression of bcl-2 through altered
allele but not the normal allele in follicular and transformed
lymphomas.
Additionally, the CREB coactivators, CBP and p300,
have also been associated hematologic malignancies [40,
41]. For example, CBP is fused to the transcription factor
(monocytic leukemia zinc ﬁnger) MOZ in M4 and M5
leukemias bearing the translocation t(8;16)(p11;13) [42].
And the chromosomal translocation t(11;16), which is
associated with acute and chronic myeloid leukemias, fuses
(Myeloid/lymphoid or mixed-lineage leukemia) the MLL
transcriptional regulator to CBP [43–46]. Together, these
ﬁndings highlight the importance of CREB and CREB
regulatory factors in modulating growth, survival, and
transformation of hematopoietic cells.
Leukemia is one of the most common forms of can-
cer. This hematologic malignancy is characterized by the
acquisition of recurring mutations and gene rearrangements
that lead to aberrant proliferation or survival advantage in
undiﬀerentiated cells. To study the possible role of CREB in
leukemogenesis, we analyzed primary bone marrow cells for
CREBexpressioninpatientswithacuteleukemia.Ourresults
demonstrated that a majority of patients with acute myeloid
leukemia and acute lymphoid leukemia overexpress CREB
two-tothreefoldinthebonemarrowatdiagnosisandrelapse
but not in remission or nonleukemic controls [18, 47]. Since
CREB was upregulated at both the protein and mRNA level
in CREB-positive (CREB+) primary AML cells, we hypoth-
esized that CREB could be ampliﬁed at the genomic level.
Fluorescent in situ hybridization (FISH) was performed on
blast cells from four CREB-overexpressing patients using a
CREB-speciﬁc bacterial artiﬁcial chromosome clone. In the
blast cells from three out of four CREB+ AML patients, we
detected three to four signals from one homolog and one
signal from the other homolog in over 250 interphase nuclei
analyzed [18]. These results indicate that certain patients
have more than the two normal copies of CREB, which
may be one potential mechanism for CREB overexpression.
However, the nature of this ampliﬁcation has not yet
been determined. AML patients that overexpress CREB are
associated with an increased risk of relapse and a decreased
in event-free survival compared to patients that do not
overexpress CREB. Studies performed in leukemia cell lines
demonstrated that CREB overexpression results in increased
proliferation and increased survival of these cells in the
absence of growth factors. Elevated CREB levels also resulted
indecreaseddiﬀerentiationofK562cellstreatedwithsodium
butyrate, while downregulation of endogenous CREB by
siRNA decreased survival and proliferation of leukemia cell
lines, suggesting that CREB modulates growth and survival
of myeloid leukemia cells. Moreover, mice overexpressing
CREB in macrophage/monocyte lineage cells develop a
myeloproliferative disease/myelodysplastic syndrome with
higher white blood counts and aberrant myelopoiesis in
both the bone marrow and spleen after one year. However,
these mice did not develop AML. Additionally, bone marrow
progenitor cells from CREB transgenic mice exhibit prop-
erties of transformed cells, such as increased proliferation,
immortalization, and hypersensitivity to growth factors in
colony assays.
WealsoexaminedtherequirementofCREBinmalignant
hematopoiesis by lentiviral shRNA downregulation of CREB
in several leukemia cell lines. Inhibition of CREB in these cell
lines suppresses leukemic cell proliferation in vitro [19]. In
vivo results, correspondingly, show that downregulation of
CREB in the Bcr-abl positive BA/F3 leukemia cells injected
into Severe Combined Immunodeﬁcient (SCID) mice inhib-
ited early leukemic progression or cell proliferation in mice,
resulting in a prolonged median survival of these mice
compared to control mice. These data suggest that CREB
is critical for progression of disease. However, these results
also demonstrate that CREB contributes to but is not
suﬃcient for leukemogenesis, and that additional mutations
are necessary for the development of leukemia.
Other groups have conﬁrmed the role of CREB in
leukemogenesis. Pigazzi et al. investigated CREB expression
in acute leukemia patients and found that 84% (73/86)
patients with ALL and 80% (32/40) patients with AML
overexpressed CREB by Western blot and ELISA analysis
[48]. They also observed that CREB was phosphorylated and
thus active at diagnosis but not in remission or in non-
leukemic controls. Furthermore, using gel shift assays, they
demonstrated that CREB binds the CRE consensus site in
bone marrow cells from leukemia patients at diagnosis, but
not in remission or control samples.
The Pigazzi group also examined the expression of the
cAMP early inducible repressor (ICER). This transcriptional
regulator represses CREB activity by competing for the CRE
consensus site. Analysis of ICER expression showed that
ICER was downregulated at diagnosis but was signiﬁcantlyAdvances in Hematology 5
increased in remission and control samples [49]. This group
further investigated ICER and its role in inhibiting leukemic
transformation by expressing ICER in HL60 and HeLa
cancer cell lines and examining colony formation in vitro.
ICER transfectants were found to have a signiﬁcantly lower
amount of colonies compared to control cells. Chromatin
immunoprecipitation experiments showed that ICER rec-
ognizes and competes for CRE elements opposing CREB
target gene expression of Signal Transducers and Activator
of Transcription-3 (STAT-3), p21, fos and bcl-2.
Additionally, in vivo experiments showed that ICER
expression in HL60 cells aﬀects cellular transformation [49].
Mice were inoculated with HL60 cells and HL60-ICER
transfectants and bone marrow engraftment and invasion
of extramedullary sites was examined. Results showed that
engraftment was unaﬀected, however, invasion into the
peripheral blood and spleen was greatly reduced in HL60-
ICER mice compared to controls. Moreover, they showed
that HL60-ICER cells had decreased angiogenic potential in
vivoastheyexhibitedadecreaseintheamountofmicrovessel
numbers and size.
6. Mir-34b Regulation of CREB
The mechanism of CREB overexpression in leukemia
remainsunknown.MicroRNAs(miRNAs)aresmallnoncod-
ing RNAs that can either positively or negatively regulate
gene expression principally through translational repression
and targeting mRNA for degradation. There is recent
evidence that microRNAs also regulate CREB expression.
Approximately 30% of human genes possess conserved
miRNA binding sites and are presumed to be regulated by
microRNAs [50]. Generally, miRNAs bind mRNA sequences
located at the 3’-untranslated region (UTR) with imper-
fect complementarity. MicroRNAs avoid target mRNA on
polysomes, that would lead to a block in translation or
mRNA degradation. The mRNA partners of microRNAs,
microRNA function, and their tissue speciﬁcity are currently
being investigated in normal and diseased patient samples to
increase our understanding of tumorigenesis.
M i c r o R N A sh a v eb e e nd e m o n s t r a t e dt oc o n t r o lav a r i e t y
of cellular pathways by inﬂuencing the expression of speciﬁc
target genes [51, 52]. Hundreds of miRNAs have been
identiﬁed to date, but their speciﬁc functions and target
mRNAs have been assigned for only a few [53]. MiRNA
expression has been demonstrated to be tissue speciﬁc, and
to control cellular diﬀerentiation, proliferation and survival,
and changes in their expression have been associated with
many diseases, including human cancer [54] .Ar o l ef o r
miRNAs in several tumors has recently been recognized,
with intrinsic tumor suppressor or oncogenic functions.
There is considerable evidence that suggest a crucial role
for miRNAs in chronic lymphocytic leukemia [55, 56], and
an involvement of miR-223 and miR-155 has already been
proposed inthepathogenesis ofAML[57,58].Inappropriate
expression of candidate miRNAs that potentially bind to
the CREB gene has been evaluated by Pigazzi group [59].
They found that miR-34b a possible candidate to target
CREB by in silico and gene expression analyses. MiR-34b
was expressed at lower levels in myeloid leukemia cell lines
compared to healthy bone marrow, in agreement with other
experiments that described low levels of the expression of
the miR-34 family of miRNA in other human cancers [60].
The restoration of miR-34b revealed a direct interaction with
the CREB-3’UTR, with reduction of the CREB protein levels
in vitro. MiR-34b was demonstrated to induce cell cycle
abnormalities, reduced anchorage independent growth, and
altered CREB target gene expression, suggesting its potential
t oa c ta sat u m o rs u p p r e s s o r .T h em o l e c u l a rm e c h a n i s m
by which miR-34 family of miRNAs suppress tumors is
currently under investigation for many cancers [61, 62].
Until now, gene expression analyses have been performed,
suggesting that the cause of tumor suppression might be
the ability to target genes related to the cell cycle pathway.
Pigazzi et al. described many of the CREB target proteins, for
example, BCL-2, Cyclins A1, B1, D, NfKB, JAK1, STAT3, as
well as many downstream protein kinases, and cell survival
signaling pathways, for example, AKT/mTOR, ERK, are
decreased.
At this time, there is no evidence of miR-34b down-
regulation, apart from the frequent deﬁciency of functional
p53 that drives their transcription in several cancer cells.
Colorectal cancer studies previously identiﬁed a methylated
miR-34b/34c promoter at chromosome 11q23, which might
have reduced p53 transcriptional activity due to deletion of
thisregion[63].TreatmentofAMLcelllineswithademethy-
lating agent and studies of the CpG island at the miR-
34b/34c promoter conﬁrmed that methylation might be one
of the mechanisms of miR-34b downregulation. Moreover,
demethylation treatment leads to a decrease in CREB protein
levels, suggesting that miR-34b is epigenetically modiﬁed
in myeloid leukemia cells to maintain tumor progression
[63]. The clinical relevance of the in vitro experiments was
substantiated by data obtained in AML patients. In fact,
expression levels of miR-34b were decreased in AML patients
compared to healthy bone marrow samples. Decreased
expression of miR-34b also correlated with increased levels
of CREB protein conﬁrming the relationship between CREB
expression and miRNA regulation.
7. Concluding Remarks
I ns u m m a r y ,w ec o n c l u d et h a tC R E Bi sap r o t o - o n c o g e n e
whose overexpression can potentiate transformation of
hematopoietic cells. However, CREB’s biologic eﬀect on pro-
liferation and survival is not suﬃcient to induce leukemias
in vivo. Similar observations have been described with other
transgenic mouse models of leukemia. AML1-ETO, K-Ras
and FLT3-internal tandem duplication (ITD) transgenic
mice, for example, develop myeloproliferative disorders but
not leukemias. Similarly, CREB in vivo contributes to the
leukemia phenotype, but additional mutations or ‘hits’ are
required for disease development.
This review discusses the role of CREB in cellular
transformation. How CREB target gene activation leads to
the transforming phenotype, however, is yet to be fully
understood. CREB has been shown to associate with a
number of cellular coactivators. However, there is evidence6 Advances in Hematology
that the interactions between CREB and its coactivators are
too weak to activate transcription of CREB target genes.
This suggests that many CREB interacting proteins are yet
to be identiﬁed. Future research will focus on identifying
additional CREB interacting proteins and the target genes
that confer a proliferative or survival advantage to myeloid
cells resulting in transformation. Once better understood,
CREB-speciﬁc signaling molecules could serve as potential
targets for therapeutic intervention.
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